Publicacions CVC -- Edit Record

	Publicacions CVC Home \| Show All \| Simple Search \| Advanced Search \| Add Record \| Import	You must login to submit this form! Login Quick Search: Field: contains: ...
	Edit the following record:

Author	...				is Editor
Title	...			Type
Year	...	Publication	...	Abbreviated Journal	...
Volume	...	Issue	...	Pages	...
Keywords	...
Abstract	Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature to predict response to immune checkpoint inhibitors in advanced solid tumors. Materials and Methods In this retrospective study, a radiomics signature was developed in patients with advanced solid tumors (including breast, cervix, gastrointestinal) treated with anti-programmed cell death-1 or programmed cell death ligand-1 monotherapy from August 2012 to May 2018 (cohort 1). This was tested in patients with bladder and lung cancer (cohorts 2 and 3). Radiomics variables were extracted from all metastases delineated at pretreatment CT and selected by using an elastic-net model. A regression model combined radiomics and clinical variables with response as the end point. Biologic validation of the radiomics score with RNA profiling of cytotoxic cells (cohort 4) was assessed with Mann-Whitney analysis. Results The radiomics signature was developed in 85 patients (cohort 1: mean age, 58 years ± 13 [standard deviation]; 43 men) and tested on 46 patients (cohort 2: mean age, 70 years ± 12; 37 men) and 47 patients (cohort 3: mean age, 64 years ± 11; 40 men). Biologic validation was performed in a further cohort of 20 patients (cohort 4: mean age, 60 years ± 13; 14 men). The radiomics signature was associated with clinical response to immune checkpoint inhibitors (area under the curve [AUC], 0.70; 95% CI: 0.64, 0.77; P < .001). In cohorts 2 and 3, the AUC was 0.67 (95% CI: 0.58, 0.76) and 0.67 (95% CI: 0.56, 0.77; P < .001), respectively. A radiomics-clinical signature (including baseline albumin level and lymphocyte count) improved on radiomics-only performance (AUC, 0.74 [95% CI: 0.63, 0.84; P < .001]; Akaike information criterion, 107.00 and 109.90, respectively). Conclusion A pretreatment CT-based radiomics signature is associated with response to immune checkpoint inhibitors, likely reflecting the tumor immunophenotype. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Summers in this issue.
Address	...
Corporate Author	...			Thesis
Publisher	...	Place of Publication	...	Editor	...
Language	...	Summary Language	...	Original Title	...
Series Editor	...	Series Title	...	Abbreviated Series Title	...
Series Volume	...	Series Issue	...	Edition	...
ISSN	...	ISBN	...	Medium	...
Area	...	Expedition	...	Conference	...
Notes	...			Approved	yes no
Location
Call Number	...			Serial
Marked	yes no	Copy		Selected	yes no
User Keys	...
User Notes	...			User File	...
User Groups	...			Cite Key	...
Related	...
File
URL	...			DOI	...
	Online publication. Cite with this text: ...

Location Field:	my name & email address

Home

SQL Search | Library Search | Show Record | Extract Citations

Help